DUBLIN, Aug. 17, 2015 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/vxcx3f/investigation) has announced the addition of the "Investigation Report on China's Nateglinide Market, 2010-2019" report to their offering.
There are about 90 million diabetes patients in today's China and 95% of them suffer from type 2 diabetes mellitus. And the number of potential patients might reach up to 200 million.
Entering China after 2000, insulin secretagogues agent is mainly used for the treatment of type 2 diabetes. Currently, there are only three kinds available in the Chinese market, namely, nateglinide, repaglinide and mitiglinide. They share the same mechanism of action, that is to say, they lower blood glucose by stimulating the release of insulin from the beta cells. Compared with sulfonylurea, insulin secretagogues agent reports shorter duration of glucose-lowering action and lower rate of hypoglycemia.
Insulin secretagogues agent can be used alone in patients with type 2 diabetes where non-drug treatment fail to work. For patients with type 2 diabetes where metformin alone fail to work, it can be used together with metformin so as to lower blood glucose better.
Developed by the Japanese company Ajinomoto, anateglinide is the new oral non-sulfonylurea drug for the treatment of type 2 diabetes mellitus (T2DM). First appearing in the Japanese market in 1999, anateglinide was marketed by Novartis in the US in 2001 and later entered China in 2003. Compared with other oral antidiabetic drugs, anateglinide features novel mechanism, fast onset, short duration of action, certain efficacy, flexible dose and good safety. Currently, anateglinide in the Chinese market mainly comes from Beijing Novartis (Trade Name: Starlix), Deyuan Pharm, Chia Tai Tianqing Pharmaceutical Group Co., Ltd (Trade Name: Bei Jia) and Nanjing Hailing Pharmaceutical Co., Ltd (Trade Name: Qifu).
Meanwhile, over ten local enterprises got the approval to produce nateglinide as they all see a huge potential market for nateglinide. However, since nateglinide came into the market later than repaglinide, its market impact still lags behind repaglinide. Therefore, it is difficult for nateglinide to substitute repaglinide in a short time.
According to this market survey, Beijing Novartis Pharma Ltd. took up a market share of about 95% for sales value in 2014 while other companies like Deyuan Pharm, Luoxin Pharmacy Group Co., Ltd and Chia Tai Tianqing Pharmaceutical Group Co., Ltd together occupied about 5% of the nateglinide market in China. The sales value of nateglinide was CNY 67 million in 2014 and CAGR during the period of 2005-2014 reached about 40%.
Key Topics Covered:
1 Related Concepts of Nateglinide
2 Market Profile of Nateglinide in China
3 Survey on Sales Status of Nateglinide in China, 2010-2014
4 Survey on Market Share of Major Manufacturers of Nateglinide in China, 2010-2014
5 Survey on Dosage Forms of Nateglinide in China, 2010-2014
6 Reference Price of Nateglinide in Chinese Hospitals in 2014
7 Major Manufacturers of Nateglinide in Chinese Market, 2010-2014
8 Market Outlook of Nateglinide in China, 2015-2019
- Beijing Novartis Pharma Ltd. - Ajinomoto - Deyuan Pharm - Luoxin Pharmacy Group Co., Ltd - Chia Tai Tianqing Pharmaceutical Group Co., Ltd - Nanjing Hailing Pharmaceutical Co., Ltd
For more information visit http://www.researchandmarkets.com/research/vxcx3f/investigation
Laura Wood, +353-1-481-1716, firstname.lastname@example.org
SOURCE Research and Markets